癌症处理上最显著的进展,发生于淋巴瘤——白血病的领域内。仅几年前,急性白血病患者往往迅速死亡,而淋巴瘤患者也迟早会死亡。近年来通过系统的研究和合理的治疗,已稳步地提高了生存率,这对儿童急性白血病、非何杰金氏淋巴瘤和成人及儿童的何杰金氏病来说更为明显。目前16岁以下的急性白血病患者,半数以上可存活5年以上,然而在使用有效的化疗以前,几乎全部患者于12个月内死亡。在何杰金氏病20年前的5年生存率低于45%,而目前已有70%以上的患者可望生存5年。 The most significant advance in cancer treatment occurs in the field of lymphoma, leukemia. Only a few years ago, patients with acute leukemia often died quickly, and patients with lymphoma died sooner or later. In recent years, through systematic research and reasonable treatment, the survival rate has been steadily improved. This is more evident in children with acute leukemia, non-Hodgkin’s lymphoma, and Hodgkin’s disease in adults and children. At present, more than half of acute leukemia patients under the age of 16 can survive for more than 5 years. However, almost all patients die within 12 months before using effective chemotherapy. The 5-year survival rate of Hodgkin’s disease 20 years ago was less than 45%, and currently more than 70% of patients are expected to survive for 5 years.